Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ADH1B | P00325 | 2/20 | 0.35 |
| ▸ | ADH1C | P00326 | 2/20 | 0.35 |
| ▸ | ADH1A | P07327 | 2/20 | 0.35 |
| ▸ | ADH7 | P40394 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19134112 | 1.00 | EPHX1 (0.35) | EPHX1ALDH1A1HSD17B10ADH1BADH1C | |
| SCHEMBL21211597 | 1.00 | EPHX1 (0.35) | EPHX1ALDH1A1HSD17B10ADH1BADH1C | |
| SCHEMBL21771233 | 0.97 | ALDH1A1 (0.39) | EPHX1ALDH1A1HSD17B10ADH1BADH1C | |
| SCHEMBL16918359 | 0.97 | ALDH1A1 (0.39) | EPHX1ALDH1A1HSD17B10ADH1BADH1C | |
| SCHEMBL24373165 | 0.95 | EPHX1 (0.42) | EPHX1ALDH1A1HSD17B10ADH1BADH1C | |
| SCHEMBL24398116 | 0.95 | EPHX1 (0.38) | EPHX1ALDH1A1HSD17B10ADH1BADH1C | |
| SCHEMBL84879 | 0.95 | — | — | |
| SCHEMBL14303471 | 0.95 | — | — | |
| SCHEMBL17286038 | 0.95 | — | — | |
| SCHEMBL18070254 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133538-A1 | TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-9918971-B2 | Aerosol formulations of granisetron and uses thereof | Luxena Pharmaceuticals, Inc. (US) | 2018-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133538-A1 | TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 | MAPT, PSEN1, PSEN2 | EPHX1 4174/4885ALDH1A1 3938/4885HSD17B10 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.